Endpoints News 生物医药· Kyle LaHucik·· 2026-10-22AI 评分31
Rezera 提交 IPO 申请以支持 NLRP3 在周围动脉疾病领域的研发
Rezera files for IPO to back NLRP3 work in peripheral artery disease
AI 导读
Rezera(前 NodThera)已进入 IPO 排队阶段,旨在为其十年期 NLRP3 项目提供资金。该管线针对周围动脉疾病,目前仍处于申报阶段,尚未上市。
正文
Rezera, the biotech that rebranded from NodThera earlier this year, has entered the queue for an initial public offering to bolster its decade-long NLRP3 efforts.
…
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news